SCHEDULE: Paramora Holding LLC Cuts Stake in Damora Therapeutics

Paramora Holding LLC has reduced its position in Damora Therapeutics to 3.39%, falling below the 5% regulatory reporting threshold.

Summary

• Paramora Holding LLC reported a beneficial ownership of 2,045,473 shares of Damora Therapeutics, Inc.
• This ownership represents 3.39% of the 60,303,212 shares of common stock outstanding as of March 17, 2026.
• The reporting person has sole voting and dispositive power over all 2,045,473 shares.
• This filing is an amendment (No. 1) to a previous Schedule 13G, indicating a change in the size of the holding.
• The reporting person now holds less than 5% of the class of securities, which triggers different reporting requirements.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative because a major shareholder has reduced their position below the 5% reporting threshold, which may indicate a cooling of conviction.

Positives

• Paramora Holding LLC remains a significant shareholder with over 2 million shares.
• The investment is classified as passive, meaning the holder does not intend to influence or change control of the company.

Negatives

• The reporting person has reduced their stake to below the 5% threshold, which can precede further liquidation.
• A reduction in stake by a major holder can signal a shift in institutional sentiment regarding the company's prospects.

Risks

• Potential for continued selling pressure on the stock price if Paramora Holding LLC continues to exit its position.
• Loss of a major anchor shareholder can increase stock volatility and reduce market confidence.

Future Outlook

The filing does not provide specific forward-looking guidance, but the certification indicates the shares are held for passive investment purposes without the intent to change or influence corporate control.

Management Comments

• I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that in the biotechnology sector, the reduction of a stake below the 5% threshold by a significant holder like Paramora Holding LLC can sometimes signal a reallocation of capital away from the issuer, potentially ahead of clinical or regulatory catalysts.

Comparison to Industry Standards

• The 3.39% stake is lower than the typical 5-10% block-holder status often seen in mid-cap biotech companies.
• Compared to peers in the therapeutic space, a sub-5% holding reduces the reporting requirements and visibility of the investor's future trades.

Stakeholder Impact

• Shareholders may experience increased price volatility due to the reduction in a major holding.
• The company loses the stability of a 5%+ block holder.

Next Steps

• Monitor for further Form 4 filings if the holder is an insider, or future 13G/13D filings if the stake increases again.
• Watch for market reaction to the reduced institutional support.

Key Dates

Recommendation

While the reduction in stake is a cautious signal, the reporting person still maintains a multi-million share position. Investors should hold and monitor if this is part of a broader exit strategy or merely a portfolio rebalancing.

Keywords

Damora Therapeutics, Paramora Holding LLC, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology